Literature DB >> 14564148

Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics.

Domenic A Sica1.   

Abstract

Congestive heart failure is a disease state distinguished by the regular presence of both renal and hepatic abnormalities in drug handling. One such abnormality involves flaws in the process of drug absorption. In most instances, congestive heart failure-related abnormalities in drug absorption are of inconsequential significance. However, this is not the case with loop diuretics. Loop diuretic action ordinarily tracks the rate and extent of absorption if a sufficient amount of diuretic has been given to exceed the threshold for diuretic effect. In congestive heart failure, both the rate and absolute amount of loop diuretic absorbed can be reduced as a function of the heart failure state itself. In this setting, drug dissolution characteristics can assume added significance. Furosemide is the loop diuretic with the widest intra- and interpatient variability of absorption. Alternatively, the loop diuretic torsemide is rapidly and fairly completely absorbed independent of the heart failure state. This pattern of absorption establishes it as the preferred loop diuretic in the otherwise diuretic-resistant heart failure patient. However, the exact role of torsemide in the outpatient management of congestive heart failure remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564148     DOI: 10.1111/j.1527-5299.2003.02399.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  15 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

Review 2.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 3.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

4.  Why Diuretics Fail Failing Hearts.

Authors:  Evan C Ray; Cary R Boyd-Shiwarski; Thomas R Kleyman
Journal:  J Am Soc Nephrol       Date:  2017-08-18       Impact factor: 10.121

Review 5.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 6.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

7.  Hypertension and end-organ disease in African Americans: case presentations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

8.  Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients.

Authors:  Dan-Dan Li; Xu-Yun Wang; Shao-Zhi Xi; Jia Liu; Liu-An Qin; Jing Jing; Tong Yin; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2016-05       Impact factor: 3.327

Review 9.  Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

Authors:  Theresa McDonagh; Iain C Macdougall
Journal:  Eur J Heart Fail       Date:  2015-01-30       Impact factor: 15.534

Review 10.  Mechanisms and management of edema in pediatric nephrotic syndrome.

Authors:  Mahmoud Kallash; John D Mahan
Journal:  Pediatr Nephrol       Date:  2020-11-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.